Appendix 1. Predicted and actual costs breakdown

	Budgeted Costs At Year-end 2020 240 Patient Scenario			Actual Costs Project end 258 Patients Enrolled		
	Per Patient Amounts in €	Total Amounts in €	Percents	Per Patient Amounts in €	Total Amounts in €	Percents
Medication						
Primary treatment Medication	345	82,800	17.9%	357	92,026	19.2%
Retreatment Medication	59	14,040	3.0%	67	17,323	3.6%
Total medication	**€ 403.50**	**€ 96,840.00**	21.0%	**€ 424**	**€ 109,349**	**22.8%**
Diagnostic Costs						
Viral Load Tests						
RNA Viral Load Lab Costs (S -4)	44	10,448	2.3%	63	17,015	3.4%
RNA Viral Load Lab Costs (S 24)	16	3,840	0.8%			
RNA Viral Load GeneXpert Cartridges	50	11,973	2.6%	63	16,129	3.4%
Total Viral Load per Enrolled Patient	**€ 109**	**€ 26,261**	**5.7%**	**€ 125**	**€ 33,143**	**6.7%**
Other Diagnostics						
ELISA	19	4,473	1.0%	7	1,745	0.4%
Basic Labs	42	10,077	2.2%			
Tests for Complications (per enrolled)	13	3,155	0.7%	60	15,514	3.2%
Retreatment Diagnostics	12	2,761	0.6%			
Total Other Diagnostis	**€ 85**	**€ 20,467**	**4.4%**	**€ 67**	**€ 17,260**	**3.6%**
Total Medication & Diagnostic Costs	**€ 598**	**€ 143,568**	**31.1%**	**€ 616**	**€ 159,752**	**33.1%**
Cameroonian Medical Support Costs						
Salaries and Site Support						
Blood Bank Teams	163	39,039	8.4%	78	20,030	4.2%
Clinical Treatment Teams	223	53,543	11.6%	148	38,268	8.0%
Project Implementation Team	471	112,963	24.4%	541	139,513	29.1%
Total Cameroonian Salaries and Site Support	**€ 856**	**€ 205,545**	**44.5%**	**€ 767**	**€ 197,812**	**41.3%**
Other Cameronian Costs (logistical & admin)	178	42,661	9.2%	155	39,889	8.3%
Total Cameroonian Medical Support Costs	**€ 1,034**	**€ 248,206**	**53.7%**	**€ 921**	**€ 237,700**	**49.6%**
Offshore Project Support Costs						
Outcome Verification (ANRS)	71	17,064	3.7%	80	20,652	4.3%
Facility Administration (GLAS)	104	25,000	5.4%	116	30,000	6.3%
Financing Costs (Fees + Interest)	58	13,838	3.0%	75	19,450	4.1%
Electronic CRF	60	14,380	3.1%	49	12,760	2.7%
Total Offshore Project Support Costs	**€ 293**	**€ 70,282**	**15.2%**	**€ 321**	**€ 82,863**	**17.3%**
Total Per Patient Costs	**€ 1,925**	**€ 462,055**	**100.0%**	**€ 1,858**	**€ 480,315**	**100.0%**
Funding						
Patient contribution	69	16,463	3%	76	19,512	4%
Outcome payments	1,658	397,800	82%	1,542	397,800	81%
Additional COVID-19 funding	302	72,500	15%	281	72,500	15%
Total funding available	**€ 2,028**	**€ 486,763**	**100%**	**€ 1,898**	**€ 489,812**	**100%**
Contingency	**€ 103**	**€ 24,709**	**5.35%**	**€ 37**	**€ 9,497**	**1.98%**

Notes. The actual total per patient cost (€1,858) is lower than the modelled total per patient cost (€1,925) because of efficiencies of scale generated through more patients having been included in treatment (n=258) than was estimated in this prediction model (n=240). For this same reason, actual total program costs (€480,315) were higher than modelled total costs (€462,055). The higher costs could be accommodated due to the 5% funding contingency allowed for in the model. During the course of the program, actual costs were regularly checked against expected expenditure to ensure that the program did not exceed the budget. At the end of the program, available funding exceeded actual costs by around €9,500, demonstrating that the applied financial model functioned accurately.

Appendix 2. Framework for evaluating Development Impact Bonds, based on proposal DFID



Appendix 3. Interviewed stakeholders

Stakeholder	Role	Number of participants
Joep Lange Institute	Investor	2
Centre Pasteur Cameroon	Service provider	2
Laboratoire de Recherche sur les Hepatites virales et la Communication en Sante	Service provider	5
ANRS	Outcome evaluator	1
Legal department PharmAccess Foundation	Intermediary	1
PharmAccess Foundation	Intermediary	3
Medical advisor and country expert	External advisor	1
Achmea Foundation	Outcome payer	3
Global Loan Agency Services (GLAS)	Intermediary	1
Health economist expert	External advisor	1
Celle de PBF, Cameroonian government	Contextual actor	1
HEREG	External advisor	1
Total	**11 interviews**	**22 persons**